

## ASX ANNOUNCEMENT

21 July 2022

# Resignation of Chief Financial Officer

---

**IDT Australia Limited (ASX: IDT)** provides the following market update. After 2 years in her role as IDT's Chief Financial Officer, Ms Ancila Desai has announced her intention to leave the Company. Ancila will finish up at IDT later this year to commence her next career opportunity and will assist IDT in the transition to a new CFO. IDT has commenced activities to secure a suitable replacement.

IDT Australia's CEO, Dr David Sparling said: "On a personal note I have very much enjoyed working with Ancila and I wish her all the very best in her next career move."

The Board of Directors and Staff at IDT wish Ancila every future success.

Ends.../

Authorised by the Board of Directors of IDT Australia Limited. For further information please contact:

***Dr David Sparling***

Chief Executive Officer - IDT Australia Limited

+61 3 9801 8888

### **About IDT**

IDT (ASX: IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

